Issue link: https://www.e-digitaleditions.com/i/1492687
8 Pharmaceutical Technology ® Bio/Pharma Outsourcing Innovation eBook 2023 PharmTech.com industry outlook and more biologics in novators seek to enter t he ma rket. T he suppor t of competent CDMOs w it h un ique exper t ise to produce cl i n ica l-sca le prod- ucts quickly and often at a lower cost than in-house production is critical to these early innovators. There have been a significant number of new entrants, de- velopers of biosimilars, biogenerics, and biobetters, as well as new developers of innovative biologics that rely on CDMOs. Further, in developing nations like China, more established companies will continue to seek partners to outsource their established products, thereby freeing up internal capacities for the devel- opment of new products in the pipeline. In newer product technology fields, such as cellular and gene treatments and antibody-drug conjugates, CDMO fa- cilities and capacities are being expanded. According to BioPlan's Top1000bio.com database, there are over 300 contract manufacturers with available capacity globally, and this number continues to expand (2). The recent economic investment retrenchment has led to discussions about overcapacity and the risks that some under-funded CDMOs may not sur- vive. Even though the total value of deals for pipeline biologics may be seeing a decline, the total number of funded assets tends to be relatively stable. An in- creasing percentage of these pipeline products, espe- cially for smaller innovators, will end up being trans- ferred to a CDMO. Most indicators for the outsourced bioprocessing industry segment appear to point to a promising future. References 1. BioPlan Associates, Inc. 19th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production (19th annual edition, April 2022). 2. BioPlan Associates. Top1000bio.com database. ■ 100% 0% 50% 10% 20% 30% 40% 60% 70% 80% 90% 2018 2017 2016 2015 2013 2014 2019 2020 2021 2022 30.1% 30.9% 30.4% 26.5% 26.3% 26.8% 41.1% 41.2% 51.0% 39.6% FIGURE 3. Non-US respondents expressing 'Strong likelihood' or 'Likelihood' for the United States as an outsourcing destination, 2013-2022. Drug Solutions Podcast: The Future of Vaccine Development Pharmaceutical Technology presents the Drug Solutions podcast, where the editors chat with industry experts from across the pharmaceutical and biopharmaceutical supply chain. Join us as experts share insights into your biggest questions—from the technologies, to strategies, to regulations related to the development and manufacture of drug products. In this episode of the Drug Solutions podcast, Jill Murphy, Editor, talks to Normand Blais, senior director of Development and Innovation in Biologics at BIOVECTRA, and Jessica Madigan, director of Business Development in Biologics at BIOVECTRA, about multiple topics under the vaccine umbrella. Blais and Madigan discuss the importance of advancements in the pipeline after COVID-19, challenges in the industry, and CDMOs differentiating themselves as vaccine leaders. For more podcast episodes, visit our website! SCAN ME!